Citius Oncology retains Jefferies to explore strategic alternatives including sale or licensing

CITIUS ONCOLOGY, INC.

Jefferies LLC appointed as exclusive financial advisor to assist in evaluating strategic alternatives.
Alternatives under consideration include partnerships, joint ventures, mergers, acquisitions, and licensing.
Company is preparing to launch LYMPHIR, FDA-approved for relapsed/refractory Stage I-III cutaneous T-cell lymphoma.
No timeline set; no assurance that a transaction will result from the review process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.